SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is seeing intense market activity as investors anticipate the final data readout from its Phase 3 REGAL trial, fueled by a surge in volume and significant institutional accumulation from major firms like BlackRock. The community is actively debating the potential for a massive short squeeze as the company approaches the 80th event milestone, with sentiment heavily focused on the transformative potential of its oncology pipeline and the likelihood of a strategic buyout.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors react to a significant earnings beat and raised full-year revenue guidance, sparking intense debate over whether the stock's growth potential justifies its complex capital structure. The community is actively weighing the company's surging backlog and defense partnerships against persistent concerns regarding dilution and the influence of market makers on share price volatility.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's XRP is currently trending as the community closely monitors the Senate Banking Committee's upcoming vote on the Clarity Act, which many believe will provide critical regulatory certainty and unlock institutional adoption. Investors are actively debating the potential impact on price and utility while expressing frustration over legislative delays and the influence of banking lobbyists.

Robo.ai, Inc. engages in the design and development of smart electric vehicles. It aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology. The company was founded in 2016 and is headquartered in Dubai, United Arab Emirates.

Robo.ai Inc. - Ordinary Shares - Class B

Robo.ai Inc.

Robo.ai Inc. is trending as traders speculate on a potential short squeeze fueled by high cost-to-borrow rates, extremely low share availability, and a new technology platform launch. Community sentiment is divided, with many anticipating a parabolic move toward double digits, while others warn of the stock's history of volatility and potential for future dilution.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is experiencing significant volatility as market participants weigh a major 200-jet order from China against broader analyst expectations for a larger deal and lingering supply chain concerns. While some community members view the order as a positive indicator of renewed market access and long-term recovery, others are focusing on execution risks and the stock's recent price fluctuations as reasons for caution.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X is trending as investors react to the company's major AI infrastructure partnership with Cerebras Systems ahead of their highly anticipated IPO. While the community is actively debating the impact of potential dilution and share offerings, sentiment remains largely driven by excitement over the company's role in the AI data center buildout and the upcoming earnings report.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and active community speculation as the Senate Banking Committee prepares for a pivotal markup session on the Clarity Act, which aims to establish a federal regulatory framework for digital assets. Investors are closely monitoring the potential for a legislative breakout or a 'sell-the-news' event, while bulls focus on the unwinding of heavy short leverage and institutional inflows as indicators of a sustained recovery.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is capturing significant investor attention as positive momentum builds behind the advancement of crypto legislation, with community members actively discussing a technical breakout and the potential for a new upward cycle. Sentiment remains mixed as the base debates the asset's long-term utility versus its speculative nature, while traders closely watch key resistance levels in hopes of a broader rally.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is experiencing high volatility as investors weigh the potential passage of the Clarity Act, which would provide a federal legal framework for stablecoins, against ongoing market skepticism regarding the company's earnings and regulatory hurdles. Community sentiment remains polarized, with many traders actively betting on a short squeeze or breakout rally while others express frustration over price swings and inconsistent institutional support compared to other crypto-linked equities.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying following the announcement of a strategic supply agreement with Lumilens, which includes an immediate purchase order and a multi-year partnership valued at up to $500 million. The community is actively discussing the stock's massive recovery from recent lows, with bulls celebrating the company's newfound commercial validation while traders debate the impact of the associated warrant structure and long-term production roadmap.

statis crypto Watchlist

Ethereum

Solana

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug

Outlook Therapeutics files FDA dispute on ONS-5010 after CRL citing effectiveness concerns; meeting with agency official set for April 2026.read more...

<ul class="summary-bullets"><li>The company stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.</li><li>Last week, Outlook Therapeutics announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.</li><li>In December 2025, the FDA issued a Complete Response Letter for ONS-5010 / LYTENAVA, saying it could not approve the treatment in its current form for wet AMD.</li></ul>Outlook Therapeutics Inc. (OTLK) shares plunged 32% in Tuesday’s pre-market trade after the company announced a proposed public offering of its common stock and accompanying warrants.Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25. The company said it expects aggregate gross proceeds of $5 million and that the offering is expected to close on Wednesday, March 25, 2026.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OTLK">Outlook Therapeutics</a> trended in the ‘extremely bearish’ territory, with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">Why Did Outlook Therapeutics Announce The Offering?</h2>Outlook Therapeutics stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.Last week, the company announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.Earlier this month, Outlook Therapeutics provided an update with respect to a meeting with the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application for its treatment of wet age-related macular degeneration (wet AMD).In December 2025, the company said that the FDA issued a Complete Response Letter for its investigational treatment, ONS-5010 / LYTENAVA (bevacizumab-vikg), stating that it cannot approve the application in its present form for the treatment of wet AMD.The company said that if the FDA approves it, bevacizumab-vikg has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the regulator for use in ophthalmology.Bevacizumab-vikg is a lab-made antibody that targets a protein called VEGF, which helps blood vessels grow. By blocking VEGF from binding to its receptors on blood vessel cells, the drug prevents the formation of new blood vessels.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Outlook Therapeutics’ proposed offering was&nbsp;criticized&nbsp;by a user on the platform, who called out the company for not giving a roadmap on how it intends to use the money, other than meeting its working capital and general corporate needs.<stembedurl>https://stocktwits.com/HarveySpecter20/message/648356634</stembedurl>Another user highlighted the lack of data on the uptake of the investigational treatment from patients.<stembedurl>https://stocktwits.com/updownsides/message/648355300</stembedurl><a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> is down 80% year-to-date and 79% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 16% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fidelity-backs-elon-musk-tesla-spacex-terafab-project-datacenters-in-space/cZ3mK7PRI0u">Elon Musk's Joint Tesla, SpaceX Terafab Project Makes A 'Ton Of Sense', Says Investor Fidelity: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Is OTLK Stock Falling Today?

Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25.

Equity

Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -26.95% and -131.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics Earnings Report: Q1 Overview

OTLK Stock Crashes 67% in a Week: Here's What You Need to Know

Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.

Wall Street Zen Downgrades Oncobiologics (NASDAQ:OTLK) to Sell

Wall Street Zen downgraded Oncobiologics from a "hold" rating to a "sell" rating in a research report on Saturday...

Futures Blast Off On First Day Of 2026 With Europe, Asia At Records

Futures Blast Off On First Day Of 2026 With Europe, Asia At Records Stocks are set to break a four-day losing streak as markets start the new year with a bang across global markets, boosted by the...

<ul class="summary-bullets"><li>The FDA said it cannot approve the application in its present form for the treatment of wet age-related macular degeneration.</li><li>This marked the second rejection for Outlook’s drug for wet AMD treatment in less than six months.</li><li>The CEO said, “We are disappointed and disagree with this decision.</li></ul>Shares of Outlook Therapeutics (<a href="https://stocktwits.com/symbol/OTLK">OTLK</a>) slumped more than 60% on Friday after it failed to secure U.S. Food and Drug Administration approval for its drug Lytenava, which is intended to treat wet age-related macular degeneration (wet AMD), a chronic eye disorder.This marked the second rejection for Outlook’s drug for wet AMD treatment in less than six months. In August, the FDA declined to approve the drug, citing insufficient evidence of effectiveness, and recommended that the company submit additional data to support its application.In the Complete Response Letter (CRL), the FDA noted that the additional mechanistic and natural history data provided in the biologics license application (BLA) resubmission do not alter the previous review conclusion, adding that the FDA cannot approve the application in its present form for the treatment of wet age-related macular degeneration.“We are disappointed and disagree with this decision, but we remain fully committed to taking all necessary steps to receive approval in the United States,” Bob Jahr, Chief Executive Officer of Outlook Therapeutics, said in a statement.Lytenava has been granted marketing authorization by the European Commission in the EU and marketing authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around OTLK trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes.<figure class="image"><img style="aspect-ratio:636/66;" src="https://news.stocktwits-cdn.com/otlk_3_PNG_39a4a7c8e1.webp" alt="Retail sentiment around OTLK trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes." width="636" height="66"></figure>However, the latest blow from the FDA has disappointed retail traders, with one user saying, “Even if they have money, they have proven approval is beyond their abilities.”<figure class="image"><img style="aspect-ratio:651/132;" src="https://news.stocktwits-cdn.com/OTLK_USER_1_PNG_ebd1b97a3d.webp" alt="latest blow from the FDA has disappointed retail traders, with one user saying, “Even if they have money, they have proven approval is beyond their abilities.”" width="651" height="132"></figure> The FDA disapproval prompted users to believe the company would do cost-cutting. With one user saying to expect the next PR to be cost-cutting and layoffs, followed by dilution, and yet another reverse split.<img src="https://news.stocktwits-cdn.com/otlk_4_PNG_f4b526073b.webp" alt="otlk 4.PNG">Shares of Outlook Therapeutics were down nearly 17% in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Outlook Therapeutics Tanks Over 60% On Another FDA Blow – Here’s How Retail Is Reacting 

OTLK Stock - The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.

A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares 

The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.

Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again

Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.read more...

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Current Price	$0.2285
Prev Close	$0.23
Open	$0.2152
Dividend Yield	0.00%
50-Day Moving Average	$0.2895
Beta	0.83
Avg. Volume	5.05M
PE Ratio	-0.21

52-Week High	$3.39
52-Week Low	$0.1611
Market Capitalization	$27.77M
EPS (Annual)	-$1.79
Price to Book	-0.39
Revenue Per Employee	$83,149.12

OTLK
Outlook Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OTLK News

OTLKOutlook Therapeutics Inc